冠心病患者血浆microRNA-9-5p的表达水平和临床意义

邓 鑫炼, 陈 柏荣
中山大学附属第五医院心血管病中心

摘要


目的：检测急性冠脉综合征、稳定型心绞痛和非冠心病患者血浆miR-9-5p的表达水平，并评价血浆miR-
9-5p的表达水平与冠心病不同临床类型相关性，探讨其在冠心病患者中的临床意义。方法：纳入68名行冠脉造影
术患者，包括急性冠脉综合征组（n=35）、稳定性心绞痛组（n=21）、冠脉造影正常者（n=12）。收集并记录纳入患
者的基础临床资料，同时采集血液标本，采用PCR检测miR-9-5p表达水平。结果：ROC曲线分析显示：miR-9-
5p预测冠心病的曲线下面积为0.890（95%CI：0.813-0.987，P＜0.001），miR-9-5p相对值等于0.885时为诊断冠心
病的最佳截断值，对应的敏感性和特异性分别为83.3％、87.5％；此外，miR-9-5p预测急性冠脉综合征的曲线下面
积为0.827（95%CI：0.721-0.933，P＜0.001），miR-9-5p相对值等于0.705时为诊断急性冠脉综合征的最佳截断值，
对应的敏感性和特异性分别为81.0％、71.4％。结论：CAD患者血浆miR-9-5p表达水平较Non-CAD患者下降；在
不同临床类型的冠心病中，ACS患者血浆miR-9-5p表达水平低于SAP患者，提示血浆miR-9-5p可能作为诊断冠心
病及其不同临床类型的潜在生物标志物。

关键词


急性冠脉综合征；冠心病；microRNA-9-5p；标志物

全文:

PDF


参考


[1]Gerhardt T, Seppelt C, Abdelwahed YS, et al. Culprit

plaque morphology determines inflammatory risk and clinical

outcomes in acute coronary syndrome. Eur Heart J. 2023.

44(38): 3911-3925.

[2]刘霄静，葛英辉.冠状动脉易损斑块的影像学诊

断研究进展.医药论坛杂志.2021.42（08）：142-145.

[3]Dzau VJ, Hodgkinson CP. RNA Therapeutics for the

Cardiovascular System. Circulation. 2024. 149(9): 707-716.

[4]Nakano S, Kohsaka S, Chikamori T, et al. JCS 2022

Guideline Focused Update on Diagnosis and Treatment in

Patients With Stable Coronary Artery Disease. Circ J. 2022.

86(5): 882-915.

[5]Collet JP, Thiele H, Barbato E, et al. 2020 ESC

Guidelines for the management of acute coronary syndromes

in patients presenting without persistent ST-segment

elevation. Eur Heart J. 2021. 42(14): 1289-1367.

[6]Damluji AA, van Diepen S, Katz JN, et al. Mechanical

Complications of Acute Myocardial Infarction: A Scientific

Statement From the American Heart Association. Circulation.

2021. 144(2): e16-e35.

[7]Xu S, Kamato D, Little PJ, Nakagawa S, Pelisek J,

Jin ZG. Targeting epigenetics and non-coding RNAs in

atherosclerosis: from mechanisms to therapeutics. Pharmacol

Ther. 2019. 196: 15-43.

[8]Chen X, Zhang X, Su C, Huang S. Long noncoding

RNA HULC in acute ischemic stroke: Association with

disease risk, severity, and recurrence-free survival and relation

with IL-6, ICAM1, miR-9, and miR-195. J Clin Lab Anal.

2020. 34(11): e23500.

[9]Feng C, Tian Q, Tang X, et al. microRNA-9a-5p

disrupts the ELAVL1/VEGF axis to alleviate traumatic brain

injury. Exp Neurol. 2024. 375: 114721.

[10]Bouzidi N, Gamra H. Relationship between serum

interleukin-6 levels and severity of coronary artery disease

undergoing percutaneous coronary intervention. BMC

Cardiovasc Disord. 2023. 23(1): 586.

[11]Cavalli G, Colafrancesco S, Emmi G, et al.

Interleukin 1α: a comprehensive review on the role of IL-

1α in the pathogenesis and treatment of autoimmune and

inflammatory diseases. Autoimmun Rev. 2021. 20(3): 102763.


Refbacks

  • 当前没有refback。